Emergent BioSolutions’ (EBS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a research note published on Friday,Benzinga reports. HC Wainwright currently has a $15.00 price objective on the biopharmaceutical company’s stock.

EBS has been the topic of several other reports. StockNews.com lowered shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Saturday, December 28th. Benchmark increased their target price on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and issued a $16.00 price target on shares of Emergent BioSolutions in a research note on Friday, September 13th.

Emergent BioSolutions Trading Down 2.2 %

Emergent BioSolutions stock opened at $9.87 on Friday. The business has a 50 day moving average price of $9.34 and a two-hundred day moving average price of $9.11. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The stock has a market cap of $534.76 million, a price-to-earnings ratio of -2.41 and a beta of 1.59. Emergent BioSolutions has a 12 month low of $1.42 and a 12 month high of $15.10.

Institutional Trading of Emergent BioSolutions

Several large investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. acquired a new stake in shares of Emergent BioSolutions in the second quarter valued at approximately $41,000. Stifel Financial Corp bought a new stake in Emergent BioSolutions in the third quarter valued at approximately $96,000. FORA Capital LLC acquired a new stake in Emergent BioSolutions during the 3rd quarter worth $103,000. Vanguard Personalized Indexing Management LLC bought a new position in shares of Emergent BioSolutions during the 2nd quarter valued at about $93,000. Finally, Morse Asset Management Inc acquired a new position in shares of Emergent BioSolutions in the second quarter valued at approximately $97,000. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.